LYNBROOK, N.Y., Feb. 25, 2015 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, announced today that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences.


    --  Cowen & Co. 35th Annual Health Care Conference (Boston, MA)

Wednesday, March 4, 2015 at 8:00 a.m. EST


    --  27(th) Annual ROTH Conference (Dana Point, CA)

Monday, March 9, 2015 at 5:30 p.m. PST (8:30 p.m. EST)

The live webcasts of these presentations can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with up to two palpable cords in the same palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. XIAFLEX is marketed in the U.S. by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium), which is now a wholly-owned subsidiary of Endo International plc. Auxilium has the following partnerships outside the U.S. for XIAFLEX in Dupuytren's contracture and Peyronie's disease; Swedish Orphan Biovitrum AB has marketing rights for XIAPEX(®) (the EU tradename for CCH) in 71 Eurasian and African countries, Actelion Pharmaceuticals Ltd. has rights in Canada, Australia, Mexico and Brazil, and Asahi Kasei Pharma Corporation in Japan. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is managing studies of CCH for frozen shoulder syndrome in a Phase 2b study, and also for cellulite. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas. For more information, please visit www.biospecifics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-announces-presentations-at-upcoming-investor-conferences-300040388.html

SOURCE BioSpecifics Technologies Corp.